Prognostic Value of Growth Differentiation Factor-15 in Patients with Coronary Artery Disease: A Meta-analysis and Systematic Review

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2023 Feb 27

PMID 36844747

Authors

Song Zhang

Panpan Hao

Jiaxin Li

Qi Zhang

Xiaoying Yin

Jiali Wang

Yuguo Chen

Affiliations

Soon will be listed here.

Abstract

Background And Aims: The predictive value of growth differentiation factor-15 (GDF-15) for individual cardiovascular outcomes remained controversial in patients with coronary artery disease (CAD). We aimed to investigate the effects of GDF-15 on all-cause death, cardiovascular death, MI and stroke in CAD patients.

Methods: We searched PubMed, EMBASE, Cochrane library and Web of Science till 30 December, 2020. Hazard ratios (HRs) were combined with fixed or random effect meta-analyses. Subgroup analyses were performed in different disease types. Sensitivity analyses were used to evaluate the stability of the results. Publication bias was tested using funnel plots.

Results: A total of 10 studies with 49,443 patients were included in this meta-analysis. Patients with the highest GDF-15 concentrations had significantly increased risk of all-cause death (HR 2.24; 95% CI: 1.95-2.57), cardiovascular death (HR 2.00; 95% CI: 1.66-2.42), MI (HR 1.42; 95% CI: 1.21-1.66) after adjusting clinical characteristics and prognostic biomarkers (hs-TnT, cystatin C, hs-CRP, and NT-proBNP) but except for stroke (HR 1.43; 95% CI: 1.01-2.03, = 0.05). For the outcome of all-cause death and cardiovascular death, subgroup analyses revealed consistent results. Sensitivity analyses showed that the results were stable. Funnel plots showed that there was no publication bias.

Conclusion: In CAD patients with elevated GDF-15 levels on admission, there were independently significant risks for all-cause death and cardiovascular death. The highest concentrations of GDF-15 had a lower predictive effect on MI than all-cause death and cardiovascular death. The association of GDF-15 with the outcome of stroke needs to be further studied.

Citing Articles

Growth/differentiation factor 15 (GDF15) expression in the heart after myocardial infarction and cardioprotective effect of pre-ischemic rGDF15 administration.

Dogon G, Rigal E, Potel E, Josse M, Rochette L, Bejot Y Sci Rep. 2024; 14(1):12949.

PMID: 38839839 PMC: 11153639. DOI: 10.1038/s41598-024-63880-5.

Acute Coronary Syndrome Subphenotypes Based on Repeated Biomarker Measurements in Relation to Long-Term Mortality Risk.

de Bakker M, Scholte N, Oemrawsingh R, Umans V, Kietselaer B, Schotborgh C J Am Heart Assoc. 2024; 13(2):e031646.

PMID: 38214281 PMC: 10926784. DOI: 10.1161/JAHA.123.031646.

Growth differentiation factor 15 predicts cardiovascular events in stable coronary artery disease.

Wang J, Han L, Ai D, Wang X, Zhang W, Xu X J Geriatr Cardiol. 2023; 20(7):527-537.

PMID: 37576485 PMC: 10412535. DOI: 10.26599/1671-5411.2023.07.007.

References

Widera C, Pencina M, Bobadilla M, Reimann I, Guba-Quint A, Marquardt I . Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem. 2013; 59(10):1497-505. DOI: 10.1373/clinchem.2013.206185. View

Wollert K, Kempf T, Wallentin L . Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017; 63(1):140-151. DOI: 10.1373/clinchem.2016.255174. View

Bonaca M, Morrow D, Braunwald E, Cannon C, Jiang S, Breher S . Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2010; 31(1):203-10. DOI: 10.1161/ATVBAHA.110.213512. View

Wollert K, Kempf T . GDF-15 in heart failure: providing insight into end-organ dysfunction and its recovery?. Eur J Heart Fail. 2012; 14(11):1191-3. DOI: 10.1093/eurjhf/hfs158. View

Wallentin L, Zethelius B, Berglund L, Eggers K, Lind L, Lindahl B . GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS One. 2013; 8(12):e78797. PMC: 3846468. DOI: 10.1371/journal.pone.0078797. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

Okrainec K, Banerjee D, Eisenberg M . Coronary artery disease in the developing world. Am Heart J. 2004; 148(1):7-15. DOI: 10.1016/j.ahj.2003.11.027. View

Lin D, Wei L, Ying Z . Model-checking techniques based on cumulative residuals. Biometrics. 2002; 58(1):1-12. DOI: 10.1111/j.0006-341x.2002.00001.x. View

Kempf T, Sinning J, Quint A, Bickel C, Sinning C, Wild P . Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ Cardiovasc Genet. 2009; 2(3):286-92. DOI: 10.1161/CIRCGENETICS.108.824870. View

10.

Schopfer D, Ku I, Regan M, Whooley M . Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study). Am Heart J. 2014; 167(2):186-192.e1. DOI: 10.1016/j.ahj.2013.09.013. View

11.

Yusuf S, Reddy S, Ounpuu S, Anand S . Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001; 104(22):2746-53. DOI: 10.1161/hc4601.099487. View

12.

Morrow D, Antman E, Charlesworth A, Cairns R, Murphy S, de Lemos J . TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000; 102(17):2031-7. DOI: 10.1161/01.cir.102.17.2031. View

13.

Kimmel M, Butscheid M, Brenner S, Kuhlmann U, Klotz U, Alscher D . Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results. Nephrol Dial Transplant. 2008; 23(4):1241-5. DOI: 10.1093/ndt/gfm785. View

14.

Schlittenhardt D, Schober A, Strelau J, Bonaterra G, Schmiedt W, Unsicker K . Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004; 318(2):325-33. DOI: 10.1007/s00441-004-0986-3. View

15.

Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker R, Cannon C . Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet.... Circulation. 2013; 129(3):293-303. DOI: 10.1161/CIRCULATIONAHA.113.004420. View

16.

Damman P, Kempf T, Windhausen F, van Straalen J, Guba-Quint A, Fischer J . Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Int J Cardiol. 2014; 172(2):356-63. DOI: 10.1016/j.ijcard.2014.01.025. View

17.

Khan S, Ng K, Dhillon O, Kelly D, Quinn P, Squire I . Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009; 30(9):1057-65. DOI: 10.1093/eurheartj/ehn600. View

18.

Li M, Duan L, Cai Y, Li H, Hao B, Chen J . Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease. Cardiovasc Diabetol. 2020; 19(1):120. PMC: 7398317. DOI: 10.1186/s12933-020-01092-7. View

19.

De Luca G, Suryapranata H, van t Hof A, de Boer M, Hoorntje J, Dambrink J . Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation. 2004; 109(22):2737-43. DOI: 10.1161/01.CIR.0000131765.73959.87. View

20.

Halkin A, Singh M, Nikolsky E, Grines C, Tcheng J, Garcia E . Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005; 45(9):1397-405. DOI: 10.1016/j.jacc.2005.01.041. View